[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GEP20104926B - Macrocyclic compounds as inhibitors of viral replication - Google Patents

Macrocyclic compounds as inhibitors of viral replication

Info

Publication number
GEP20104926B
GEP20104926B GEAP20059674A GEAP2005009674A GEP20104926B GE P20104926 B GEP20104926 B GE P20104926B GE AP20059674 A GEAP20059674 A GE AP20059674A GE AP2005009674 A GEAP2005009674 A GE AP2005009674A GE P20104926 B GEP20104926 B GE P20104926B
Authority
GE
Georgia
Prior art keywords
inhibitors
viral replication
macrocyclic compounds
methods
compo
Prior art date
Application number
GEAP20059674A
Inventor
Machender R Madduru
Benjamin T Woodard
Peter J Stengel
John A Josey
George A Doherty
April L Kennedy
Yutong Jiang
Kevin R Condroski
Steven W Andrews
Steven M Wenglowsky
Lawrence M Blatt
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of GEP20104926B publication Critical patent/GEP20104926B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention refers to macrocylic compo¬unds, as well as compositions, including pharma¬ceutical compositions, comprising a subject compo¬und. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis.
GEAP20059674A 2004-03-30 2005-03-29 Macrocyclic compounds as inhibitors of viral replication GEP20104926B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55816104P 2004-03-30 2004-03-30
US56241804P 2004-04-14 2004-04-14
US61246004P 2004-09-22 2004-09-22
US61238104P 2004-09-22 2004-09-22

Publications (1)

Publication Number Publication Date
GEP20104926B true GEP20104926B (en) 2010-03-25

Family

ID=35005653

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP20059674A GEP20104926B (en) 2004-03-30 2005-03-29 Macrocyclic compounds as inhibitors of viral replication

Country Status (16)

Country Link
EP (1) EP1749007A2 (en)
JP (1) JP4950026B2 (en)
AP (1) AP2006003763A0 (en)
AR (1) AR050321A1 (en)
AU (1) AU2005228894B9 (en)
BR (1) BRPI0509467A (en)
CA (1) CA2560897C (en)
CU (1) CU23787B7 (en)
EA (1) EA012389B1 (en)
EC (1) ECSP066959A (en)
GE (1) GEP20104926B (en)
IL (1) IL177917A0 (en)
MA (1) MA28548B1 (en)
NO (1) NO20064933L (en)
NZ (1) NZ549697A (en)
WO (1) WO2005095403A2 (en)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
MX2007000428A (en) 2004-07-15 2008-03-05 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin.
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5667745B2 (en) * 2005-03-08 2015-02-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Process for producing macrocyclic compounds
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7601686B2 (en) 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7470664B2 (en) 2005-07-20 2008-12-30 Merck & Co., Inc. HCV NS3 protease inhibitors
CN101263156A (en) 2005-07-25 2008-09-10 因特蒙公司 Novel macrocyclic inhibitors of hepatitis C virus replication
CA2617096C (en) * 2005-07-29 2013-12-24 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
AR055395A1 (en) 2005-08-26 2007-08-22 Vertex Pharma INHIBITING COMPOUNDS OF THE ACTIVITY OF SERINA PROTEASA NS3-NS4A OF HEPATITIS C VIRUS
US7772183B2 (en) * 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN101336229B (en) 2005-12-23 2012-06-13 西兰岛药物有限公司 Modified lysine-mimetic compounds
WO2008008776A2 (en) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EA017448B1 (en) 2006-07-13 2012-12-28 Ачиллион Фармасьютикалз, Инк. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2357494T3 (en) * 2006-11-16 2011-04-27 Bristol-Myers Squibb Company MACROCYCLIC PEPTIDES AS INHIBITORS OF HEPATITIS C.
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008079266A2 (en) 2006-12-21 2008-07-03 Wyeth Synthesis of pyrrolidine compounds
EA200900969A1 (en) * 2007-01-08 2010-02-26 Феномикс Корпорейшн MACROCYCLIC INHIBITORS OF HEPATITIS C PROTEASE
WO2008096002A1 (en) * 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Hcv inhibiting macrocyclic phosphonates and amidophosphates
JP2010519339A (en) 2007-02-26 2010-06-03 アキリオン ファーマシューティカルズ，インコーポレーテッド Tertiary amine substituted peptides useful as HCV replication inhibitors
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CA2686138A1 (en) * 2007-05-03 2008-11-13 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8178491B2 (en) * 2007-06-29 2012-05-15 Gilead Sciences, Inc. Antiviral compounds
AP2009005073A0 (en) 2007-06-29 2009-12-31 Gilead Sciences Inc Antiviral compounds
AR067180A1 (en) * 2007-06-29 2009-09-30 Gilead Sciences Inc ANTIVIRAL COMPOUNDS
SE531698C2 (en) 2007-07-12 2009-07-07 Respiratorius Ab New bronchodilating a, b unsaturated amides
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
WO2009082697A1 (en) 2007-12-21 2009-07-02 Avila Therapeutics, Inc. Hcv protease inhibitors and uses thereof
US8778877B2 (en) 2007-12-21 2014-07-15 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
BRPI0821836A2 (en) 2007-12-24 2015-06-16 Tibotec Pharm Ltd Macrocyclic indoles as inhibitors of hepatitis c virus
MX2010010660A (en) * 2008-04-11 2010-10-25 Hoffmann La Roche New ruthenium complexes as catalysts for metathesis reactions.
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AU2009278075B2 (en) * 2008-08-07 2013-07-04 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (en) 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
BRPI0918653A2 (en) 2008-09-17 2015-12-01 Boehringer Ingelheim Int ns3 inhibitor combination of hcv prosthesis with interferon and ribavirin.
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR101762842B1 (en) 2008-12-10 2017-08-04 아칠리온 파르마세우티칼스 인코포레이티드 New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EA019341B1 (en) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Nucleoside phosphoramidates
EP2671888A1 (en) 2008-12-23 2013-12-11 Gilead Pharmasset LLC 3',5'-cyclic nucleoside phosphate analogues
CL2009002208A1 (en) 2008-12-23 2010-10-29 Gilead Pharmasset Llc A compound (2s) -2 - ((((2r, 3r, 4r, 5r) -5- (2-amino-6-ethoxy-9h-purin-9-yl) -4-fluoro-3-hydroxy-4 -methyltetrahydrofuran-2-yl) methoxy) (hydroxy) phosphorylamino) propanoic acid, viral arn replication inhibitors; pharmaceutical composition; and its use in the treatment of infection with hepatitis c, West Nile virus, among others.
WO2010097229A2 (en) 2009-02-27 2010-09-02 Ortho-Mcneil-Janssen Pharmaceuticals Inc Amorphous salt of a macrocyclic inhibitor of hcv
EP2417134B1 (en) 2009-04-08 2017-05-17 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors
KR20120023072A (en) 2009-05-12 2012-03-12 브리스톨-마이어스 스큅 컴퍼니 Crystalline forms of (s)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorohphenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
DK2429296T3 (en) 2009-05-12 2018-03-12 Albany Molecular Res Inc 7 - ([1,2,4,] TRIAZOLO [1,5, -A] PYRIDIN-6-YL) -4- (3,4-DICHLORPHENYL) -1,2,3,4- TETRAHYDROISOQUINOLINE AND USE thereof
WO2010132437A1 (en) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
TWI598358B (en) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
CA2767692C (en) 2009-07-07 2017-03-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition for a hepatitis c viral protease inhibitor
JP2013501068A (en) 2009-08-05 2013-01-10 アイディニックス ファーマシューティカルズ インコーポレイテッド Macrocyclic serine protease inhibitor
EP2483273A4 (en) * 2009-09-28 2013-05-01 Hoffmann La Roche Novel macrocyclic inhibitors of hepatitis c virus replication
KR20120106942A (en) 2009-10-30 2012-09-27 베링거 인겔하임 인터내셔날 게엠베하 Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
MA34013B1 (en) 2010-01-25 2013-02-01 Enanta Pharm Inc Hepatitis C inhibitors c
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011123668A2 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Stereoselective synthesis of phosphorus containing actives
EP2609923B1 (en) 2010-03-31 2017-05-24 Gilead Pharmasset LLC Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
BR112013012078A2 (en) 2010-11-15 2019-09-24 Abbvie Inc nampt and rock inhibitors
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
CN103534256B (en) 2010-12-30 2016-08-10 益安药业 Macrocyclic hepatitis c serine protease inhibitors
JP2014506255A (en) 2010-12-30 2014-03-13 エナンタ ファーマシューティカルズ インコーポレイテッド Phenanthridine macrocyclic hepatitis C serine protease inhibitor
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
KR20150023722A (en) 2012-06-12 2015-03-05 애브비 인코포레이티드 Pyridinone and pyridazinone derivatives
MX360452B (en) 2012-10-19 2018-11-01 Bristol Myers Squibb Co Hepatitis c virus inhibitors.
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
KR20160005334A (en) 2013-03-14 2016-01-14 아칠리온 파르마세우티칼스 인코포레이티드 Novel Processes for Producing Sovaprevir
WO2014145507A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
JP2016513732A (en) 2013-03-15 2016-05-16 アキリオン ファーマシューティカルズ，インコーポレーテッド Sobaprevir polymorph and method for producing the same
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
PL3650014T3 (en) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
CN110709096B (en) 2017-05-05 2023-10-31 泽兰德制药公司 Cell gap junction communication regulator and application thereof in treatment of diabetic eye disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR022061A1 (en) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd INHIBITING PEPTIDES OF HEPATITIS C, A PHARMACEUTICAL COMPOSITION CONTAINING THEM, THE USE OF THE SAME TO PREPARE A PHARMACEUTICAL COMPOSITION, THE USE OF AN INTERMEDIATE PRODUCT FOR THE PREPARATION OF THESE PEPTIDES AND A PROCEDURE FOR THE PREPARATION OF ANOGRAPH .
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
JP3889708B2 (en) * 2000-11-20 2007-03-07 ブリストル−マイヤーズ スクイブ カンパニー Hepatitis C tripeptide inhibitor
US6867185B2 (en) * 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
CA2369711A1 (en) * 2002-01-30 2003-07-30 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis c virus
CA2369970A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
CA2370396A1 (en) * 2002-02-01 2003-08-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor tri-peptides
US6828301B2 (en) * 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
AU2003248535A1 (en) * 2002-05-20 2003-12-12 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
CA2540858C (en) * 2003-10-14 2009-12-08 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
TWI361195B (en) * 2004-01-30 2012-04-01 Medivir Ab Hcv ns-3 serine protease inhibitors

Also Published As

Publication number Publication date
NZ549697A (en) 2009-12-24
AR050321A1 (en) 2006-10-18
CA2560897C (en) 2012-06-12
MA28548B1 (en) 2007-04-03
JP4950026B2 (en) 2012-06-13
AU2005228894B2 (en) 2011-08-25
CA2560897A1 (en) 2005-10-13
CU23787B7 (en) 2012-03-15
JP2007531749A (en) 2007-11-08
ECSP066959A (en) 2006-12-20
AP2006003763A0 (en) 2006-10-31
EA012389B1 (en) 2009-10-30
EA200601467A1 (en) 2007-06-29
WO2005095403A3 (en) 2005-12-01
NO20064933L (en) 2006-12-15
EP1749007A2 (en) 2007-02-07
BRPI0509467A (en) 2007-09-11
CU20090209A7 (en) 2011-04-26
IL177917A0 (en) 2006-12-31
WO2005095403A2 (en) 2005-10-13
AU2005228894A1 (en) 2005-10-13
AU2005228894B9 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
GEP20104926B (en) Macrocyclic compounds as inhibitors of viral replication
TNSN06308A1 (en) Macrocyclic compounds as inhibitors of viral replication
HK1109617A1 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same c
IL195025A (en) Cyclopropyl fused indolobenzazepine derivatives and pharmaceutical compositions comprising the same as anti-hcv medicament
PL1677827T3 (en) Combinations for hcv treatment
IL188320A (en) Macrocyclic inhibitors of hepatitis c virus, pharmaceutical compositions comprising them and their manufacture
IL188227A (en) Macrocyclic compounds, combinations and pharmaceutical compositions comprising them, uses thereof as inhibitors of hepatitis c virus and processes for their preparation
GEP20104960B (en) USE OF [D-MeALa]3-[EtVal]4-CYCLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID [D-MeAla]3-[EtVal]4-CYCLOSPORIN
HK1122292A1 (en) Anti-viral compounds
WO2008133753A3 (en) Anti-viral compounds
DE60319820D1 (en) PYRAZOLOE1,5-ATPYRIMIDIN COMPOUNDS AS ANTIVIRAL AGENTS
HK1122291A1 (en) Anti-viral compounds
IL221361A0 (en) Novel macrocyclic inhibitors of hepatitis c virus replication
WO2007001406A3 (en) Aryl-containing macrocyclic compounds
WO2006039488A3 (en) Hcv ns3-ns4a protease inhibition
WO2003053349A3 (en) Inhibitors of hepatitis c virus
WO2007047146A3 (en) Inhibitors of viral replication
MX2009009473A (en) Compounds for the treatment of hepatitis c.
IL190478A0 (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
WO2009029384A3 (en) Compounds for the treatment of hepatitis c
ZA200703157B (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
TW200611905A (en) Macrocyclic compounds as inhibitors of viral replication
HK1134676A1 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same c
UA104754C2 (en) Combination of a nucleoside polymerase inhibitor with a macrocyclic protease inhibitor and use thereof in the treatment of hepatitis c, liver fibrosis and impaired liver function
ZA200800715B (en) Novel macrocyclic inhibitors of hepatitis C virus replication